Regrettably, CRC patients harboring somatic KRAS mutations are not eligible to such therapies, and indeed, KRAS mutations have been recognized as predictive markers of resistance to anti-EGFR therapies [13–15]. The gene discussed is KRAS; the disease is colorectal carcinoma.